Chemotherapy for invasive bladder cancer

Urology

Volumn 47, Issue 4, 1996, Pages 602-614

  Malkowicz, S Bruce ^a   Vaughn, David J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; GALLIUM NITRATE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PIRITREXIM; TAXANE DERIVATIVE; TRIMETREXATE; VINBLASTINE;

ADJUVANT THERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MEDICAL DECISION MAKING; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASTIC SURGERY; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SURGICAL APPROACH; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASM INVASIVENESS; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER NEOPLASMS;

EID: 0029946957     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80506-8     Document Type: Review

References (105)

1. Simon R: Design and conduct of clinical trials, in Devita VT, Hellman S, and Rosenberg SA (Eds): Cancer Principles and Practice of Oncology, 4th ed. Philadelphia, JB Lippincott, 1993, pp 418-440.
2. Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, and Whitmore W: Cis-dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60: 917-923, 1976.
3. Soloway MS: Cis-diamminedichloroplatinum (II) (DDP) in advanced urothelial cancer. J Urol 120: 716-719, 1978.
4. Merrin C: Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 119: 493-495, 1978.
5. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, and Braun DW Jr: Methotrexate: an active drug in bladder cancer. Cancer 47: 1246-1250, 1981.
6. Oliver RT: Methotrexate as salvage or adjunctive therapy for primary invasive carcinoma of the bladder. Cancer Treat Rep 65 (suppl): 179-182, 1981.
7. Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, and Smith PH: Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 56: 668-672, 1984.
8. Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MP, and Krakoff IH: Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature. Cancer 39: 279-285, 1977.
9. Knight EW, Pagand M, Hahn RG, and Horton J: Comparison of 5-FU and doxorubicin in the treatment of carcinoma of the bladder. Cancer Treat Rep 67: 514-515, 1983.
10. Blumenreich MS, Yagoda A, Natale RB, and Watson RC: Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50: 435-438, 1982.
11. Richards B, Newling D, Fossa S, Bastable JR, Denis L, Jones WB, and de Pauw M: Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II trial. Cancer Treat Rep 67: 575-577, 1983.
12. Gad-el-Mawla N, Ziegler JL, Hamza R, Elserafi M, and Khaled H: Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder. Cancer Treat Rep 68: 419-421, 1984.
13. Yagoda A: Chemotherapy of urothelial tract tumors. Cancer 60: 574-585, 1987.
14. Harker WG, Meyer FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, and Torit FM: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol 3: 1463-1470, 1985.
15. Scher HI, and Norton L: Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol 8: 316-341, 1992.
16. Troner M, Birch R, Omura GA, and Williams S: Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group Trial. J Urol 137: 660-662, 1987.
17. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
18. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, and Usui T: Usefulness and limitations of methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662-665, 1990.
19. Tannock I, Gospodarowicz M, Connolly J, and Jewett M: M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 142: 289-292, 1989.
20. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
21. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422, 1988.
22. Loehrer PJ Sr, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, and Einhorn LH: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 12: 483-488, 1994.
23. Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DO, Quinlivan S, Tao Y, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408-414, 1993.
24. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Finn L, and Gutterman JU: Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82: 667-672, 1990.
25. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, and Amato RJ: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13: 2272-2277, 1995.
26. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, and Kilbourn RG: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055, 1990.
27. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10: 1066-1073, 1992.
28. Bahnson RR, Smith D, and Trump D: Adjuvant chemotherapy for bladder cancer. Standard of care or unproven therapy. Surg Oncol Clin North Am 4: 287-294, 1994.
29. Scher HI: Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin Oncol 17: 555-565, 1990.
30. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, et al: Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6: 1590-1596, 1988.
31. Stockle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, Huber C, and Hohenfellner R: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148: 302-307, 1992.
32. Stockle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thuroff JW, Huber C, and Hohenfellner R: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153: 47-52, 1995.
33. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, and Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145: 459-467, 1991.
34. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, and Sonntag RW: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152: 81-84, 1994.
35. Freiha F, Reese J, and Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155: 495-500, 1996.
36. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, and Glick JH: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
37. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005-1018, 1990.
38. Keating JP, Zincke H, Hahn RG, and Morgan WR: Extended experience of neo-adjuvarit M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder. Prog Clin Biol Res 353: 119-127, 1990.
39. Keating JP, Zincke H, Hahn RG, and Morgan WR: Extended experience of neoadjuvant M-VAC chemotherapy for T1-4 N0-M0 transitional cell carcinoma of the urinary bladder, in Splinter TA, and Scher HI (Eds): Neoadjuvant Chemotherapy in Invasive Bladder Cancer. New York, Wiley-Liss, 1990, pp 119-127.
40. Pizzocaro G, Pisani E, Dormia E, Piva L, Maggioni A, and Minervini G: Neoadjuvant medium-dose methotrexate, cisplatin in category T3b-T4a (N0M0) bladder cancer, in Splinter TA, and Scher HI (Eds): Neoadjuvant Chemotherapy in Invasive Bladder Cancer. New York, Wiley-Liss, 1990, pp 129-136.
41. Checile G, Montie J, Pontes JE, and Bukowski RM: Neo-adjuvant intra-arterial chemotherapy in locally advanced bladder cancer, in Splinter TA, and Scher HI (Eds): Neoadjuvant Chemotherapy in Invasive Bladder Cancer. New York, Wiley-Liss, 1990, pp 153-161.
42. Boutan-Laroze A, Mahjoubi M, Droz JP, Charrot P, Fargeot P, Kerbrat P, Caty A, Voisin PM, Spielmann M, Rey A, et al: MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder: the French Federation of Cancer Centers experience. Eur J Cancer 27: 1690-1694, 1991.
43. Vogelzang NJ, Moormeier JA, Awan AM, Weichselbaum RR, Farah R, Straus FH 2d, Schoenberg HW, Chodak GW, and Straus FH: Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol 149: 753-757, 1993.
44. Sternberg CN, Arena MG, Calabresi F, De Carli P, Platania A, Zeuli M, Giannarelli D, Cancrini A, and Pansadoro V: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer 72: 1975-1982, 1993.
45. Paz-Ares L, Lianes P, Diaz-Puente M, Rivera F, Passas J, Costas P, Mendiola C, and Cortes-Funes H: CMV frontline chemotherapy in transitional bladder carcinoma. Ann Oncol 4: 147-150, 1993.
46. Herr HW, and Scher HI: Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12: 975-980, 1994.
47. Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosl G, Morse MJ, Sogani PC, Watson RC, Dershaw DD, Reuter V, et al: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470-474, 1988.
48. Splinter TA, Pavone-Macaluso M, Jacqmin D, Roberts JT, Carpentier P, de Pauw M, and Sylvester R: A European Organization for Research and Treatment of Cancer-Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response. J Urol 148: 1793-1796, 1992.
49. Seidman AD, and Scher HI: The evolving role of chemotherapy for muscle infiltrating bladder cancer. Semin Oncol 18: 585-595, 1991.
50. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, Scherr D, Bosl GL, and Scher HI: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with five year follow-up. J Clin Oncol 12: 1394-1401, 1994.
51. Splinter TA, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, Soloway M, Vogelzang NJ, van Tinteren H, and Herr H: The prognostic value of the pathologic response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 147: 606-608, 1992.
52. Fung CY, Shipley WU, Young RH, Griffin PP, Convery KM, Kaufman DS, Althausen AF, Heney NM, and Prout GR Jr: Prognostic factors in invasive bladder carcinoma in a prospective trial of pre-operative adjuvant chemotherapy and radiotherapy. J Clin Oncol 9: 1533-1542, 1991.
53. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, and Scher HI: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC. J Clin Oncol 13: 1384-1390, 1995.
54. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, and Benedict WF: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1256-1261, 1992.
55. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, and Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264, 1994.
56. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama, T, Toyoshima K, Yamamoto T, et al: An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70: 2493-2498, 1992.
57. Coppin C, Gospodarowicz M, Dixon P, Tannock I, Zee B, and Sullivan L: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or radical radiation. Proc Annu Meet Soc Clin Oncol 11: A607, 1992.
58. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, Dunn J, Boulas J, and Latief T: Neoadjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67: 608-615, 1991.
59. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, Escudero A, Jimenez Cruz F, and Isorna S: Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153: 964-973, 1995.
60. Rintala E, Hannisdahl E, Fossa SD, Hellsten S, and Sander S: Neo-adjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol 27: 355-362, 1993.
61. Ghersi D, Stewart LA, Parmar MK, Coppin C, Martinez-Pineiro J, Raghavan D, and Wallace MA: Does neo-adjuvant cisplatin-based chemotherapy improve survival of patients with locally advanced bladder cancer: an analysis of individual patient data from randomized clinical trials. Br J Urol 75: 206-213, 1995.
62. Soloway MS, Morris CR, and Sudderth B: Radiation therapy and cis-diammine-dichloroplatinum (II) in transplantable and primary murine bladder cancer. Int J Radiat Oncol Biol Phys 5: 1355-1360, 1979.
63. Shipley WU, Prout GR Jr, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, Englander L, Barton BA, and Hafermann MD: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935, 1987.
64. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, Martz K, Venner P, and Hammond E: Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25: 783-790, 1993.
65. Jakse G, Frommhold G, and zur-Nedden D: Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder. Cancer 55: 1659-1664, 1985.
66. Kragelj B, Jereb B, Kragelj L, and Stanonik M: Concurrent vinblastine and radiation therapy in bladder cancer. Cancer 70: 2885-2890, 1992.
67. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, and Efird JT: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329: 1377-1382, 1993.
68. Tester W, Caplan R, Heaner J, Venner P, Whittington R, Byhardt R, True L, and Shipley W: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14: 119-126, 1996.
69. Given RW, Parsons JT, McCarley D, and Wajsman Z: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 46: 499-505, 1995.
70. Lundberg JH, and Chitambar CR: Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 50: 6466-6470, 1990.
71. Seligman PA, Moran PL, Schleicher RB, and Crawford ED: Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am J Hematol 41: 232-240, 1992.
72. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, and O'Brien WJ: Inhibition of leukemic HL60 cell growth by transferrin gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72: 1930-1936, 1988.
73. Chitambar CR, Narasimhan J, Guy J, Sem DS, and O'Brien WJ: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 51: 6199-6201, 1991.
74. Crawford ED, Saiers JH, Baker LH, Costanzi JH, and Bukowski RM: Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group Study. Urology 38: 355-357, 1991.
75. Warrell RP Jr, Coonley CJ, Straus DJ, and Young CW: Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51: 1982-1987, 1983.
76. Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M, and Staszewski H: Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73: 1487-1490, 1984.
77. Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, and Bosl GJ: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68: 2561-2565, 1991.
78. Schultz P, Bajorin D, Kelly WK, Motzer R, Bosl GJ, and Scher HI: Combination gallium nitrate and 5-fluorouracil for platinum-resistant metastatic transitional cell carcinoma of the bladder. Proc Annu Meet Assoc Cancer Res 34: A1209, 1993.
79. McCaffrey J, Hilton S, Bajorin D, Mazumdar A, Amsterdam A, Kim B, and Scher H: Gallium nitrate and 5-fluorouracil combination vs M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) in patients with advanced urothelial tract tumors: a phase II randomized trial. Proc Annu Meet Am Soc Clin Oncol 14: A600, 1995.
80. Berger NA: Alkylating agents, in DeVita VT, Hellman S, and Rosenberg SA (Eds): Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia, JP Lippincott, 1993, pp 400-409.
81. Witte R, Loehrer P, Dreicer R, Williams S, and Elson P: Ifosfamide (IFX) in advanced urothelial carcinoma: an ECOG trail. Proc Annu Meet Soc Clin Oncol 12: A707, 1993.
82. Schmidt AS, Ruther U, and Eisenberger F: First-line therapy with ifosfamide and etoposide for the treatment of advanced bladder cancer. J Urol 149: 318A, 1993.
83. Gad-el-Mawla N, Khaled H, and Abdel-Wareth A: Epirubicin, ifosfamide combination chemotherapy in invasive bladder cancer. Proc Annu Meet Soc Clin Oncol 9: A530, 1990.
84. Mahjoubi M, Kattan J, Droz JP, Philippot I, Pautier R, Boutan-Laroze A, Azab M, and Theodore C: Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer. Eur J Cancer 29A: 285-286, 1993.
85. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, and Loehrer PJ: Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12: 2271-2276, 1994.
86. Dreicer R, Roth B, Propert K, Einhorn L, Hudes G, and Loehrer P: E5892 vinblastine, ifosfamide, and gallium nitrate (VIG) in advanced carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Annu Meet Soc Clin Oncol 14: A659, 1995.
87. Niell HB, Rangel C, Miller A, and Cox C: The activity of antimicrotubular agents in human bladder tumor cell lines. Proc Annu Meet Assoc Cancer Res 34: A1207, 1993.
88. Rowinsky EK, and Donehower RC: Paclitaxel (Taxol). N Engl J Med 332: 1004-1014, 1995.
89. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, and Loehrer PJ: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol 12: 2264-2270, 1994.
90. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
91. Roth BJ, and Bajorin DF: Advanced bladder cancer: the need to identify new agents in the post M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). World J Urol 153: 894-900, 1995.
92. Cortes JE, and Pazdur R: Docetaxel. J Clin Oncol 13: 2643-2655, 1995.
93. McCaffrey J, Hilton S, Bajorin D, Mazumdar M, Amsterdam A, Kim B, and Scher H: Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin-based chemotherapy: a phase II trial. Proc Annu Meet Soc Clin Oncol 14: A607, 1995.
94. Jackson RC, Leopold WR, Hamelehle KL, and Fry DW: Pre-clinical studies with trimetrexate: a review of conclusions and unanswered questions. Semin Oncol 15: (suppl 2) 1-7, 1988.
95. Witte RS, Elson P, Khandaker J, and Trump DL: An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73: 688-691, 1994.
96. Feun LG, Savaraj N, Benedetto P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, and Clendeninn NJ: Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst 83: 51-55, 1991.
97. deWit R, Kaye SB, Roberts JT, Stoter G, Scott J, and Verweij J: Oral Piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67: 388-390, 1993.
98. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, and Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′2′ difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
99. Moore M, Anderson J, Burris H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, et al: A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol 14: A473, 1995.
100. Pollera CF, Ceribelli A, Crecco M, and Calabresi F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-184, 1994.
101. Stadler W, Kuzel T, Raghavan D, Levine E, Vogelzang N, and Dorr A: A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 14: A638, 1995.
102. Wadler S, Lembersky B, Atkins M, Kirkwood J, and Petrelli N: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 9: 1806-1810, 1991.
103. Logothetis CJ, Hossan E, Sella A, Dexeus FH, and Amato RJ: Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 83: 285-288, 1991.
104. Logothetis C, Dieringer P, Ellerhorst J, Amato R, Sella A, Zukiwski A, and Kilbourn R: A 61% response rate with 5-fluorouracil, interferon alpha-2b and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma. Proc Annu Meet Am Assoc Cancer Res 33: A1323, 1992.
105. Bacoyiannis C, Skarlos D, Aravantinos G, Fountzilas G, Tsavaris N, Milathianakis C, and Kosmidis P: Cisplatin (CDDP), interferon A2B (IFN-A), and 5 fluorouracil (5-FU) (CIF) for advanced urothelial cancer (AUC). A phase II study. Proc Annu Meet Am Soc Clin Oncol 14: A612, 1995.